Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Sasha Bernatsky¹, Rosalind Ramsey-Goldman ², Murray Urowitz ³, John Hanly ⁴, Caroline Gordon ⁵, Michelle Petri ⁶, Ellen M Ginzler ⁷, Daniel J Wallace ⁸, Sang-Cheol Bae ⁹, Juanita Romero-Diaz ¹⁰, MA Dooley ¹¹, Christine Peschken ¹², David A Isenberg ¹³, Anisur Rahman ¹⁴, Susan Manzi ¹⁵, Soren Jacobsen ¹⁶, S Sam Lim ¹⁷, Ronald F Van Vollenhoven ¹⁸, Ola Nived ¹⁹, Diane Kamen ²⁰, Cynthia Aranow ²¹, Jill Buyon ²², Guillermo Ruiz-Irastorza ²³, Ian Bruce ²⁴, Dafna Gladman ²⁵, Paul Fortin ²⁶, Joan T. Merrill ²⁷, Jorge Sanchez-Guerrero ²⁸, Kenneth C Kalunian ²⁹, Kristjan Steinsson ³⁰, Manuel Ramos ³¹, Asad Zoma ³², Thomas Stoll ³³, Munther A Khamashta ³⁴, Murat Inanc ³⁵ and Ann E Clarke ³⁶, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷State University of New York Downstate Medical Center, Brooklyn, NY, ⁸Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ¹¹UnC Kidney Centre, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, Canada, ¹³Centre for Rheumatology, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Allegheny Health Network, Pittsburg, PA, ¹⁶Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²NYU School of Medicine, New York, ²³Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ²⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ²⁷Okalahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Toronto Western Hospital, Toronto, ON, Canada, ²⁹UC San Diego School of Medicine, LaJolla, CA, ³⁰Landspitali, University Hospital, Reykjavik, Iceland, ³¹Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³²Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ³³University of Glasgow, Kilbride, Scotland, United Kingdom, ³⁴King's College London School of Medicine, London, United Kingdom, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶University of Calgary, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 73 • 2019 ACR/ARP Annual Meeting
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Ramadan Ali¹, Julia Weiner ¹, Alex Gandhi ¹, Shanea Estes ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: 6-gingerol, the major bioactive compound of ginger root, is known to have anti-inflammatory and anti-oxidative effects. Indeed, ginger has been employed for millennia as…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 700 • 2019 ACR/ARP Annual Meeting
Sleep Quality Among Patients with Systemic Lupus Erythematosus
Alexandra Schwab¹ and Diane Kamen ², ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Poor sleep quality is a frequent concern among patients with systemic lupus erythematosus (SLE) and contributes to fatigue and other comorbidities. This study investigates…
Abstract Number: 1019 • 2019 ACR/ARP Annual Meeting
Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts
Justine Shum¹, Yogita Ghodke-Puranik ², Regine Tipon ², Jessica Dorschner ³, Danielle Vsetecka ³, Shreyasee Amin ⁴, Ashima Makol ⁵, Floranne Ernste ⁴, Thomas Osborn ⁵, Kevin Moder ³, Vaidehi Chowdhary ³, Uma Thanarajasingam ⁶, Vilija Oke ⁷, Iva Gunnarsson ⁷, Agneta Zickert ⁷, Maria Zervou ⁸, Elisabet Svenungsson ⁹, George Goulielmos ⁸ and Timothy Niewold ², ¹NYU School of Medicine, New York, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, ³Mayo Clinic, Rochester, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸University of Crete, Crete, Greece, ⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Type I interferon (IFN) is an important mediator in the pathogenesis of systemic lupus erythematosus. Serum type I IFN levels clearly vary between SLE…
Abstract Number: 1147 • 2019 ACR/ARP Annual Meeting
Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients
Allen Anandarajah¹, Caroline Thirukumaran ¹, Kelly callahan ¹, Jennifer Anolik ¹ and Christopher Ritchlin ², ¹University of Rochester Medical Center, Rochester, NY, ²Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with a high rate of hospitalizations and is the sixth highest reason for 30-day readmissions among all medical…
Abstract Number: 1580 • 2019 ACR/ARP Annual Meeting
Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Renata Hansen¹, Titilola Falasinnu ², Julia Simard ³, Mikkel Faurschou ⁴ and Søren Jacobsen ⁵, ¹Copenhagen Lupus and Vasculitis Clinic, Denmark, Stanford, CA, ²Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Hovedstaden, Denmark, ⁵Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Denmark
Background/Purpose: Development of comorbidity over time in patients with systemic lupus erythematosus (SLE) is not well characterized. To provide a detailed and comprehensive picture hereof,…
Abstract Number: 1620 • 2019 ACR/ARP Annual Meeting
T-cell Exhaustion in Prolonged Remission SLE Patients
Francisco Treviño-Tello¹, Guadalupe Lima ¹, Juan Jakez-Ocampo ², Luis Llorente ¹, Yemil Atisha-Fregoso ¹ and Hilda Fragoso-Loyo ³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: Cellular exhaustion is a cellular dysfunction characterized by the progressive loss of the effector function, and an increased expression of multiple inhibitory receptors. Exhaustion…
Abstract Number: 1851 • 2019 ACR/ARP Annual Meeting
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
S Sam Lim¹, Gaobin Bao ¹, Charles Helmick ², Charmayne Dunlop-Thomas ³ and Cristina Drenkard ¹, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ³Emory University, Atlanta, Georgia
Background/Purpose: African Americans (AA) are more likely to experience psychosocial and environmental stressors and develop SLE than whites. Increasing frequency of racial discrimination is associated…
Abstract Number: 2043 • 2019 ACR/ARP Annual Meeting
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Natalie Sippl¹, Francesca Faustini ¹, Karine Chemin ¹, Iva Gunnarsson ² and Vivianne Malmström ³, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: Arthritis is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course.…
Abstract Number: 2523 • 2019 ACR/ARP Annual Meeting
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
April Jorge¹, Na Lu ² and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA
Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public…
Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
W. Winn Chatham ¹, Richard Furie ², Amit Saxena ³, Philip Brohawn ⁴, Erik Schwetje⁵, Gabriel Abreu ⁶ and Raj Tummala ⁵, ¹University of Alabama Medical Center, Birmingham, AL, ²Zucker School of Medicine at Hofstra/Northwell, New York, NY, ³NYU Langone Orthopedic Center, New York, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…
Abstract Number: 2792 • 2019 ACR/ARP Annual Meeting
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Valentin Ritschl¹, Ricardo Ferreira ², Rúben Fernandes ², Eduardo Santos ², Essi Juutila ³, Erika Mosor ¹, Kim Fligelstone ⁴, Helena Gaspar ⁵, Linda Schraven ⁶, Judy Ammerlaan ⁷, Georg Stummvoll ⁸, Maria João Salvador ², Janet Poole ⁹, Cornelia van den Ende ¹⁰, Carina Boström ¹¹ and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Metropolia University of Applied Sciences, Helsinki, Finland, ⁴Federation of European Scleroderma Associations, Tournai, Belgium, ⁵Portuguese League Against Rheumatic Diseases, Portugal, Portugal, ⁶Federation of European Scleroderma Associations, Sweden, Sweden, ⁷University Medical Centre, Utrecht, Netherlands, ⁸Klinikum Malcherhof Baden, Baden, Austria, ⁹University of New Mexico, Albuquerque, NM, ¹⁰Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune Connective Tissue Disorders (CTDs), including Mixed Connective Tissue Disorders (MCTD), systemic sclerosis (SSc) and systemic lupus erythematous (SLE) can lead to Raynaud phenomenon,…
Abstract Number: 75 • 2019 ACR/ARP Annual Meeting
Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Hadijat Makinde¹, Elise Mike ², Chaim Putterman ³, Deborah Winter ⁴ and Carla Cuda ⁵, ¹Northwestern University, Chicago, IL, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, New York, NY, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, ⁵Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. More than 50% of patients experience neuropsychiatric symptoms of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].